New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk DOI Open Access
Keungmo Yang, Myeong Jun Song

Nutrients, Journal Year: 2023, Volume and Issue: 15(18), P. 3970 - 3970

Published: Sept. 14, 2023

Metabolism-associated fatty liver disease (MAFLD) is a multifaceted that involves complex interactions between various organs, including the gut and heart. It defined by hepatic lipid accumulation related to metabolic dysfunction, obesity, diabetes. Understanding intricate interplay of gut–liver–heart crosstalk crucial for unraveling complexities MAFLD developing effective treatment prevention strategies. The gut–liver participates in regulation inflammatory processes through host–microbiome interactions. Gut microbiota have been associated with development progression MAFLD, its dysbiosis contributes insulin resistance, inflammation, oxidative stress. Metabolites derived from enter systemic circulation influence both heart, resulting axis playing an important role MAFLD. Furthermore, growing evidence suggests endothelial inflammation may contribute increased risk cardiovascular (CVD). Additionally, dysregulation metabolism also lead cardiac dysfunction heart failure. Overall, molecular pathways CVD patients This review emphasizes current understanding as foundation optimizing patient outcomes

Language: Английский

Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group DOI
Stuart McPherson, Matthew J. Armstrong, Jeremy Cobbold

et al.

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2022, Volume and Issue: 7(8), P. 755 - 769

Published: April 28, 2022

Language: Английский

Citations

52
Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality DOI Creative Commons
Cheng Han Ng, Zhen Yu Wong, Nicholas Chew

et al.

Frontiers in Cardiovascular Medicine, Journal Year: 2022, Volume and Issue: 9

Published: Aug. 8, 2022

Hypertension (HTN) is a common comorbidity in non-alcoholic fatty liver disease (NAFLD) affecting up to 40% of individuals. However, the impact HTN and its control on outcomes NAFLD remains unclear. Therefore, we aimed examine survival longitudinal cohort patients.

Language: Английский

Citations

44
Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review DOI Open Access
Kiarash Riazi, Mark G. Swain, Stephen E. Congly

et al.

Nutrients, Journal Year: 2022, Volume and Issue: 14(21), P. 4556 - 4556

Published: Oct. 28, 2022

Non-alcoholic fatty liver disease (NAFLD) is a significant public health concern worldwide with complex etiology attributed to behavioural, environmental, and genetic causes. The prevalence of NAFLD estimated be 32.4% constantly rising. Global data, however, indicate considerable heterogeneity among studies for both incidence. Identifying variables that affect the epidemiological measures essential all stakeholders, including patients, researchers, healthcare providers, policymakers. Besides helping research on etiology, it helps identify individuals at risk disease, which in turn will outline focus preventive help fittingly tailor individualized treatments, targeted prevention, screening, or treatment programs. Several suggest differences severity by race ethnicity, may linked lifestyle, diet, metabolic comorbidity profile, background, others. Race/ethnicity as can provide valuable information regarding biological people similar cultural, dietary, geographical backgrounds. In this review, we examined existing literature race/ethnicity susceptibility discussed contributing such differences, diet physical activity, susceptibility. We also reviewed limitations NAFLD.

Language: Английский

Citations

43
The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities DOI Creative Commons
M. V. Maevskaya, Yu. V. Kotovskaya, В. Т. Ивашкин

et al.

Terapevticheskii arkhiv, Journal Year: 2022, Volume and Issue: 94(2), P. 216 - 253

Published: Feb. 15, 2022

The National Consensus was prepared with the participation of Medical Association for Study Multimorbidity, Russian Scientific Liver Society, Endocrinologists, Gerontologists and Geriatricians, Society Preventive Cardiology, Professional Foundation Promotion Medicine Fund PROFMEDFORUM. aim multidisciplinary consensus is a detailed analysis course non-alcoholic fatty liver disease (NAFLD) main associated conditions. definition NAFLD given, its prevalence described, methods diagnosing components such as steatosis, inflammation fibrosis are described. association number cardio-metabolic diseases (arterial hypertension, atherosclerosis, thrombotic complications, type 2 diabetes mellitus, obesity, dyslipidemia, etc.), chronic kidney risk developing hepatocellular cancer were analyzed. review non-drug treatment modern opportunities pharmacotherapy presented. possibilities new molecules in considered: agonists nuclear receptors, antagonists pro-inflammatory molecules, etc. positive properties disadvantages currently used drugs (vitamin E, thiazolidinediones, etc.) Special attention paid to multi-target ursodeoxycholic acid molecule complex multifactorial disease. Its anti-inflammatory, anti-oxidant cytoprotective properties, ability reduce steatosis an independent factor development cardiovascular pathology, hepatic through modulation autophagy considered. influence glucose lipid homeostasis have anticarcinogenic effect has been demonstrated. statement advanced provisions practitioners optimize diagnosis related common pathogenetic links diseases.

Language: Английский

Citations

40
Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease DOI Open Access
Gashaw Hassen, Abhishek Singh,

Gizeshwork Belete

et al.

Cureus, Journal Year: 2022, Volume and Issue: unknown

Published: May 30, 2022

Nonalcoholic fatty liver disease (NAFLD), also named metabolic dysfunction-associated (MAFLD), is a progressive spectrum encompassing simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. It clinically silent leading to multiple extra-hepatic complications/comorbidities. an independent risk factor for cardiovascular (CVD), increasing susceptibility hypertension, atherosclerosis, arrhythmia, myocardial dysfunction, cardiac valve deformation, venous thrombosis through putative mechanisms including systemic inflammation, endothelial oxidative stress, insulin resistance, altered lipid metabolism. Eventually, it increases the CVD prevalence, incident, fatality, contributing huge health care burden. In fact, becoming cause of mortality among patients with NAFLD. Other cardiometabolic factors coexisting NAFLD may accelerate synergistic development CVD, which warrants assessment targeting diabetes mellitus (DM), obesity, dyslipidemia be integral part care. Monitoring biomarkers (glucose, glycosylated hemoglobin [HbA1c], insulin, lipids, lipoproteins), (CV) scores (American College Cardiology/American Heart Association [ACC/AHA] or Framingham), subclinical atherosclerosis (coronary artery calcification [CAC], carotid intima-media thickness [CIMT], plaque) are recommended prediction reduction. There no universally accepted treatment NAFLD, lifestyle changes weight loss at least 10% mainstay management. Combination therapy ezetimibe statins have cardioprotective effect help reduce fat. Despite being emerging its rapidly pattern affecting quarter global population, remains overlooked undetected, unlike other traditional factors. Hence, we conducted comprehensive narrative review shed more light on importance screening in patients. PubMed indexed relevant articles published from 2002 2022 (20 years) were searched April using medical subject headings (MeSH) as "nonalcoholic disease" [Mesh] AND "cardiovascular diseases" [Mesh]. Evidence 40 observational studies, three clinical trials, one case series, 45 reviews, four systematic reviews meta-analyses, meta-analysis summarized epidemiologic data, pathophysiologic mechanisms, features, diagnostic modalities, overlapping management, perceived challenges literacy regarding attributed

Language: Английский

Citations

40
High Remnant Cholesterol Level Potentiates the Development of Hypertension DOI Creative Commons
Mingming Chen, Xuewei Huang,

Chengsheng Xu

et al.

Frontiers in Endocrinology, Journal Year: 2022, Volume and Issue: 13

Published: Feb. 9, 2022

Emerging evidence suggests an association between remnant cholesterol (RC) and vascular damage hypertension. However, this has not been explored in a large-scale population China, temporal relationship RC hypertension also needs to be investigated.We conducted retrospective cross-sectional study 2,199,366 individuals longitudinal 24,252 with repeated measurements of lipid profile blood pressure at least 3-year follow-up. The logistic model was used explore the components analysis. Cox analyze high (HRC) baseline subsequent incidence or HRC. cross-lagged panel applied hypertension.RC level as continuous variable had highest correlation among profiles, including RC, low-density lipoprotein cholesterol, total non-high-density triglycerides, odds ratio 1.59 (95% confidence interval: 1.58-1.59). In cohort, HRC associated incident We further using analysis, results showed that increase preceded development hypertension, rather than vice versa.RC unexpected prevalence Moreover, might precede suggesting potential role

Language: Английский

Citations

39
Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease DOI
Olufunto O. Badmus, Terry D. Hinds, David E. Stec

et al.

Current Hypertension Reports, Journal Year: 2023, Volume and Issue: 25(8), P. 151 - 162

Published: May 16, 2023

Language: Английский

Citations

39
Metabolic Syndrome and Its Association with Nonalcoholic Steatohepatitis DOI Creative Commons
Fernando Bril, Arun J. Sanyal, Kenneth Cusi

et al.

Clinics in Liver Disease, Journal Year: 2023, Volume and Issue: 27(2), P. 187 - 210

Published: Feb. 26, 2023

Language: Английский

Citations

35
Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions DOI Creative Commons

Gao-Xin Xu,

Wei Song, Chao Yu

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2023, Volume and Issue: 11

Published: May 16, 2023

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are emerging as the leading causes of worldwide. These conditions can lead to cirrhosis, cancer, failure, other related ailments. At present, transplantation remains sole treatment option for end-stage NASH, a rapidly growing socioeconomic burden. Kupffer cells (KCs) dominant population macrophages that reside in liver, playing crucial role innate immunity. Their primary function includes phagocytosing exogenous substances, presenting antigens, triggering immune responses. Moreover, they interact with during pathogenesis NAFLD, this crosstalk may either delay or exacerbate progression. Stimulation by endogenous signals triggers activation KCs, resulting expression various inflammatory factors chemokines, such NLRP3, TNF-α, IL-1B, IL-6, contributing cascade. In past 5 years, significant advances have been made understanding biological properties functions KCs including their interactions tissue molecules, underlying molecular mechanisms, signaling pathways, relevant therapeutic interventions. Having comprehensive these mechanisms characteristics enormous potential guiding future strategies prevention NAFLD.

Language: Английский

Citations

28
Sex Differences in Association Between Gut Microbiome and Essential Hypertension Based on Ambulatory Blood Pressure Monitoring DOI Creative Commons

Preeti Dinesh Virwani,

Gordon Qian,

Matthew S.S. Hsu

et al.

Hypertension, Journal Year: 2023, Volume and Issue: 80(6), P. 1331 - 1342

Published: April 19, 2023

Background: Sex differences in the pathogenesis of hypertension exist. While gut microbiota (GM) has been associated with hypertension, it is unclear whether there are sex-linked association between GM and hypertension. Methods: We conducted a cross-sectional study to investigate sex associations characterized by shotgun sequencing, GM-derived short-chain fatty acids, 24-hour ambulatory blood pressure 241 Hong Kong Chinese (113 men 128 women; mean age, 54±6 years). Results: The hypertensive group was alterations; however, significant β-diversity composition versus normotensive groups were only observed women not under various statistical models adjusting for following covariates: sex, body mass index, sodium intake estimated spot urine analysis, glucose, triglycerides, low- high-density lipoprotein cholesterol, smoking, menopause, liver status. Specifically, Ruminococcus gnavus , Clostridium bolteae Bacteroides ovatus significantly more abundant women, whereas Dorea formicigenerans women. No bacterial species found be men. Furthermore, total plasma acids propionic acid independent predictors systolic diastolic but Conclusions: dysregulation strongly men, which may mediated through acid. Our work suggests that an important consideration while assessing role development treatment

Language: Английский

Citations

27